NCT01198769View on ClinicalTrials.gov

Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

PHASE4CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

November 11, 2010

Primary Completion Date

April 18, 2011

Study Completion Date

April 18, 2011

Conditions

Infections, Rotavirus

Interventions

BIOLOGICAL

Rotarix TM

Oral, 2 doses

Trial Locations (1)

100

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY